CN110772433A - 一种复合多种后生元赋活精华素及制备方法 - Google Patents
一种复合多种后生元赋活精华素及制备方法 Download PDFInfo
- Publication number
- CN110772433A CN110772433A CN201911120976.1A CN201911120976A CN110772433A CN 110772433 A CN110772433 A CN 110772433A CN 201911120976 A CN201911120976 A CN 201911120976A CN 110772433 A CN110772433 A CN 110772433A
- Authority
- CN
- China
- Prior art keywords
- fermentation product
- filtrate
- extract
- essence
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004913 activation Effects 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 6
- 239000002131 composite material Substances 0.000 title claims description 4
- 230000003698 anagen phase Effects 0.000 title description 3
- 239000000047 product Substances 0.000 claims abstract description 195
- 238000000855 fermentation Methods 0.000 claims abstract description 179
- 230000004151 fermentation Effects 0.000 claims abstract description 179
- 239000000706 filtrate Substances 0.000 claims abstract description 127
- 239000000284 extract Substances 0.000 claims abstract description 85
- 241000186660 Lactobacillus Species 0.000 claims abstract description 54
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 54
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 50
- 235000009566 rice Nutrition 0.000 claims abstract description 50
- 241000471262 Ardisia japonica Species 0.000 claims abstract description 46
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims abstract description 39
- 241000235347 Schizosaccharomyces pombe Species 0.000 claims abstract description 38
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 31
- 239000001257 hydrogen Substances 0.000 claims abstract description 31
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 29
- 235000013923 monosodium glutamate Nutrition 0.000 claims abstract description 28
- 229940073490 sodium glutamate Drugs 0.000 claims abstract description 28
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 27
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 26
- 240000004922 Vigna radiata Species 0.000 claims abstract description 26
- 235000010721 Vigna radiata var radiata Nutrition 0.000 claims abstract description 26
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 claims abstract description 26
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims abstract description 26
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000008367 deionised water Substances 0.000 claims abstract description 25
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 25
- 235000020712 soy bean extract Nutrition 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 14
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims abstract description 14
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims abstract description 13
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims abstract description 13
- 229960002446 octanoic acid Drugs 0.000 claims abstract description 13
- 239000001384 succinic acid Substances 0.000 claims abstract description 13
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 claims abstract 4
- 238000003756 stirring Methods 0.000 claims description 97
- 239000000686 essence Substances 0.000 claims description 72
- 241000209094 Oryza Species 0.000 claims description 48
- 230000001804 emulsifying effect Effects 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 31
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 28
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 28
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 28
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 28
- 239000011265 semifinished product Substances 0.000 claims description 27
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 claims description 25
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 claims description 25
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 24
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 24
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 claims description 24
- 229910052708 sodium Inorganic materials 0.000 claims description 24
- 239000011734 sodium Substances 0.000 claims description 24
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 22
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 22
- 239000006166 lysate Substances 0.000 claims description 22
- 241001534815 Hypsizygus marmoreus Species 0.000 claims description 20
- 150000001720 carbohydrates Chemical class 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000001569 carbon dioxide Substances 0.000 claims description 11
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 11
- 229940075894 denatured ethanol Drugs 0.000 claims description 11
- 238000007599 discharging Methods 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 229910001220 stainless steel Inorganic materials 0.000 claims description 11
- 239000010935 stainless steel Substances 0.000 claims description 11
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 241000235346 Schizosaccharomyces Species 0.000 claims description 7
- 238000013329 compounding Methods 0.000 claims description 3
- 230000000280 vitalizing effect Effects 0.000 claims 7
- 239000012530 fluid Substances 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 208000010668 atopic eczema Diseases 0.000 abstract description 17
- 230000000172 allergic effect Effects 0.000 abstract description 14
- 206010015150 Erythema Diseases 0.000 abstract description 7
- 238000005562 fading Methods 0.000 abstract description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract description 4
- 231100000321 erythema Toxicity 0.000 abstract description 4
- 240000007594 Oryza sativa Species 0.000 abstract 2
- 229940049906 glutamate Drugs 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 32
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 8
- 230000003020 moisturizing effect Effects 0.000 description 8
- 206010037844 rash Diseases 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 241001537183 Hypecoum Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- YWJXCIXBAKGUKZ-HJJNZUOJSA-N Bergenin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]2C3=C(O)C(OC)=C(O)C=C3C(=O)O[C@@H]21 YWJXCIXBAKGUKZ-HJJNZUOJSA-N 0.000 description 3
- XULPLJSODQQHPH-UHFFFAOYSA-N Bergenin Natural products OCC1OC2C(OC(=O)c3cc(O)c(CO)c(O)c23)C(O)C1O XULPLJSODQQHPH-UHFFFAOYSA-N 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000035992 intercellular communication Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- -1 polytetrafluoroethylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000004511 skin melanocyte Anatomy 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/87—Application Devices; Containers; Packaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明涉及一种复合多种后生元赋活精华素，按重量百分比计，其包括：8.0～13.0％的丁二醇、2.0～3.0％的辛酸/癸酸/琥珀酸甘油三酯、2.0～3.0％的聚谷酸氨钠、0.5～1.0％的矮地茶杆提取物、0.5～1.0％的酵母菌/大米发酵产物滤液、0.5～1.0％的裂殖酵母菌丝体发酵产物滤液、0.5～1.0％的乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、0.5～1.0％的乳酸杆菌发酵产物、0.5～1.0％的芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、0.5～1.0％的嗜热链球菌发酵产物、0.1～0.2％的胶态银和65.3～79.4％的去离子水；所述的精华素置于一密封容器中，精华素中注入有氢气。本发明可以达到修复皮肤的效果，注入氢气的活性物组合对降低过敏红斑量和降低过敏褪红起疹再发性具有突出的作用。
Description
技术领域
本发明属于护肤品技术领域，尤其涉及一种复合多种后生元赋活精华素及制备方法。
背景技术
在近年来大量的研究中发现，后生元有着和益生活菌类似的功效，目前，后生元来源主要是由乳酸杆菌和双歧杆菌发酵代谢而得产物，后生元使用避免了益生活菌生物利用率低与效果不稳定的难题，经由添加使用多种的益生活菌发酵代谢产生的后生元滤液，对于皮肤细胞抑制脂质过氧化反应与自由基清除的能力，大大的提升皮肤抗氧化的作用。
针对面部皮肤过敏性发红的原因，有很多复杂的因素形成，过敏性皮肤发炎有分为即刻型与迟发型两种，荨麻疹与药疹是归类为即刻型，湿疹与过敏性皮炎属于迟发型，接触性皮炎是指接触某种物质后，产生的红斑、水肿与痛痒感，一般能使大多数女性患者产生的接触性皮炎，产生的皮肤红、肿、痛、痒，大都是不当使用化妆品所致，因此，除了常规的医院抗组织胺与激素药物治疗之外，如何改善过敏性的肤质与恢复皮肤正常的机制，乃是需要长期的皮肤护理机制所完成。
人为因素的长期重金属化妆品的使用与面部激素滥用，造成毒素残留在皮肤表皮，使得皮肤变得易过敏，导致角质层变薄，对于外在的环境冷热易产生过敏起红疹，另外，生活不正常与工作压力，皮肤新陈代谢失调，也会使角质层原本保护防御机制的功能受到彻底的损坏。
过敏性发红的荨麻疹的致病原因很多，一般没有发烧、恶心、呕吐、气喘现象，有皮肤瘙痒症状。另外过敏原有鱼、虾、蟹、动物羽毛、花粉、蘑菇、荨麻、药物、日光、细菌、寄生虫等。人们在日常生活中，由于接触的物品和吃的食物太多、太广泛，一时不容易查清病因，自觉剧痒，容易抓破红疹水泡后可引起感染，因此造成有些人反复发生皮肤发红的荨麻疹。
发明内容
基于背景技术存在的问题，本发明的目的主要解决的技术问题在于一种复合多种后生元赋活精华素和制备方法，对于经常性过敏褪红的人群，有很好的治愈功效，能够提供复原过程之中皮肤原生状态所需的能量。
为了达到目的，本发明提供的技术方案为：
本发明提供一种复合多种后生元赋活精华素，按重量百分比计，其包括：8.0～13.0％的丁二醇、2.0～3.0％的辛酸/癸酸/琥珀酸甘油三酯、2.0～3.0％的吡咯烷酮羧酸钠、2.0～3.0％的聚谷酸氨钠、1.0～2.0％的生物糖胶-1、1.0～1.5％的透明质酸钠、0.5～1.0％的矮地茶杆提取物、0.5～1.0％的海茴香愈伤组织培养物滤液、0.5～1.0％的酵母菌/大米发酵产物滤液、0.5～1.0％的裂殖酵母菌丝体发酵产物滤液、0.5～1.0％的乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、0.5～1.0％的乳酸杆菌发酵产物、0.5～1.0％的芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、0.5～1.0％的二裂酵母发酵产物溶胞物、0.5～1.0％的嗜热链球菌发酵产物、0.1～0.2％的胶态银和65.3～79.4％去离子水；所述的精华素置于一密封容器中，精华素中注入有氢气。
优选地，按重量百分比计，其包括：10％的丁二醇、2.4％的辛酸/癸酸/琥珀酸甘油三酯、2.6％的吡咯烷酮羧酸钠、2.5％的聚谷酸氨钠、1.3％的生物糖胶-1、1.2％的透明质酸钠、0.9％的矮地茶杆提取物、0.7％的海茴香愈伤组织培养物滤液、0.6％的酵母菌/大米发酵产物滤液、0.8％的裂殖酵母菌丝体发酵产物滤液、0.9％的乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、0.7％的乳酸杆菌发酵产物、0.6％的芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、0.7％的二裂酵母发酵产物溶胞物、0.8％的嗜热链球菌发酵产物、0.1％的胶态银和73.2％的去离子水；所述的精华素置于一密封容器中，精华素中注入有氢气。
优选地，所述的矮地茶杆提取物由矮地茶杆通过粉碎机粉碎，利用超临界萃取方式，以二氧化碳配合适量的变性乙醇当成溶剂，调整适当的温度与压力，泄压后制得。
辛酸/癸酸/琥珀酸甘油三酯由中链三甘油酯与琥珀酸合成的油脂，具有比重接近于1的特性，与水的比重接近，具有稳定乳化的能力，并有丝滑不粘腻的触感，其良好的特殊保湿能力，有助于降低表皮水分散失率，给皮肤带来良好的紧致与优异的成膜性。
吡咯烷酮羧酸钠，源自于L-谷氨酸的天然保湿剂，也是存在于皮肤的天然保湿因子之一，具有优异皮肤的亲和性与被吸收，对皮肤有优异的润泽与补充保湿能力因子。
聚谷酸氨钠发现于传统的纳豆之中，是一种有粘性的氨基酸阴离子聚合物，一般也通称γ-聚谷氨酸，该聚合物是以谷氨酸为结构单元，通过α-氨基与β-羧基所形成酰胺键的同构形多胜肽生物高分子，由于数个亲水基团的所形成大量的氢键，使得天然保湿的聚谷氨酸钠具有很强的吸水性与保湿性。
生物糖胶-1本身是聚多糖物质，主要是使用玉米活大豆作为反应基质发酵工艺而得，多糖分子结构为线性结构，多糖序列由三种多糖体所组成，分别为L-岩藻糖、D-半乳糖、半乳糖醛酸所组成，已经证实的岩藻糖成分，能够参与细胞间的沟通与协同作用，细胞间的沟通就是细胞间生物信号的交换，皮肤细胞里的例如角化细胞、朗格罕式细胞、黑色素细胞等，通过细胞间的沟通，使得皮肤应变侵袭产生保护作用，而岩藻糖可以起到一个炎症信使消除剂的作用，可以缓解皮肤发炎疼痛，阻碍过敏反应的扩展。
利用天然枯草杆菌发酵的透明质酸钠，与一般化学合成的透明质酸钠有很大的差异性，精制过的透明质酸钠，对比合成的效果，发现保水的能力与时间，都优于合成的透明质酸钠，尤其是保水薄膜停留在皮肤角质层的时间，大大的提高。
矮地茶别名又名紫金牛在传统的中药疗效里，主要是具有止咳祛痰、解毒清血的功效，植物杆中的有效成分分别为岩白菜素1号与2号，最主要利用了超临界的提取方式，提高了岩白菜素的总量。
海茴香本身是海边植物衍生到陆上的有机体，通过干细胞反应生成器提取其植物干细胞，经由低压冻干法而得，此种植物干细胞生成滤液能与皮肤细胞相结合，对于皮肤黑色素细胞里的酪氨酸脢有抑制作用，活化内皮细胞的生成与纤维母细胞的增生，促进胶原蛋白的生成，缩短伤口的愈合与修复时间。
乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液对于皮肤伤口有减少过度发炎反应与缩短愈合时间有显著的功效，抑制伤口发炎的能力与消炎药阿司匹林相当，另外，对于因过敏产生的异位性皮肤炎修复，也有显著功效。
二裂酵母发酵产物溶胞物为双歧杆菌代谢产物，溶孢物本身含有包括维他命B群、矿物质、氨基酸等有益护肤的小分子，对于皮肤因紫外线照射产生的炎症与细胞DNA损坏，有协同修复作用，另外，对于紫外线照射皮肤产生的自由基产生的光老化现象，有一定清除自由基效果。
一种复合多种后生元赋活精华素的制备方法，其特征在于：其包括以下步骤：
(1)将丁二醇、吡咯烷酮羧酸钠、聚谷酸氨钠、生物糖胶-1、透明质酸钠和去离子水混合加热至75～80℃搅拌至完全溶解，得到混合物；
(2)将步骤(1)中得到混合物倒入真空均质乳化机内，开始搅拌，搅拌速度为500～700rpm，均质速度为1600～2000rpm，抽真空至0.03～0.05Mpa,均质搅拌3-10分钟；
(3)泄去真空压力，将辛酸/癸酸/琥珀酸甘油三酯加入真空均质乳化机内，开启搅拌速度500～700rpm，均质速度1600～2000rpm，抽真空均质搅拌2-5分钟；
(4)泄去真空压力，将矮地茶杆提取物、海茴香愈伤组织培养物滤液、酵母菌/大米发酵产物滤液、裂殖酵母菌丝体发酵产物滤液、乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、乳酸杆菌发酵产物、芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、二裂酵母发酵产物溶胞物、嗜热链球菌发酵产物、胶态银依次加入真空均质乳化机内，均质搅拌5分钟；
(5)继续搅拌待温度降至35℃后出料，用80～120目不锈钢滤网过滤装桶备用，得到精华素半成品；
(6)将半成品注入到密封容器中，在半成品内注入氢气，氢气浓度控制在0.5ppm～5ppm，得到包装成品。
本发明所述的真空均质乳化机是生产药用软膏、高档膏霜、乳液等的通用设备，可以通过市场上购买而得。其工作原理是：物料通过乳化锅内上部的中心搅拌、聚四氟乙烯刮板始终迎合搅拌锅形体，扫净挂壁粘料，使被刮取的物料不断产生新界面，再经过叶片与回转叶片的剪断、压缩、折叠，使其搅拌、混合而向下流往锅体下方的均质机处，物料再通过高速旋转的切割轮与固定的切割套之间所产生的强力的剪断、冲击、乱流等过程，物料在剪切缝中被切割，迅速破碎成200nm-2um的微粒，由于乳化罐内处于真空状态，物料在搅拌过程中产生的气泡被及时抽走。采用抽真空的方式，使所生产的制品在搅拌过程中不再混入气泡，从而保证可制造出富有光泽、细腻及延展性良好的优质产品。
优选地，步骤(4)中的矮地茶杆提取物由矮地茶杆通过粉碎机粉碎，利用超临界萃取方式，以二氧化碳配合适量的变性乙醇当成溶剂，调整适当的温度与压力，泄压后制得。
优选地，步骤(2)中，搅拌速度为600rpm，均质速度为1800rpm。
优选地，步骤(2)中，真空均质乳化机抽真空至0.04Mpa。
优选地，步骤(3)中，搅拌速度为600rpm，均质速度1800rpm。
优选地，步骤(6)中，密封容器中氢气浓度控制在3ppm。
采用本发明提供的技术方案，与现有技术相比，具有如下有益效果：
1、本发明中的矮地茶杆提取物有利于降低皮肤上有害菌几率，避免了皮肤因油脂分泌与生活作息不正常产生的金黄色葡萄球菌与座疮杆菌，另外，具有调理皮肤细胞正常新陈代谢的功能，起到加速皮肤疹斑修复效果。
2、本发明通过将氢气注入在精华素中，对精华素中的多种活性物起到催化/激活作用，提高了组分活性，对经常性过敏褪红肤质具有明显的修复效果。
3、本发明的精华素中包含多种活性物，能够加强皮肤一般抗氧化与保湿的功效，达到一般护肤品长期保养的效果。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅是本发明的一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其它实施例，都属于本发明保护的范围。
实施例1
本实施例涉及一种复合多种后生元赋活精华素,按重量百分比计，其包括：10％的丁二醇、2.4％的辛酸/癸酸/琥珀酸甘油三酯、2.6％的吡咯烷酮羧酸钠、2.5％的聚谷酸氨钠、1.3％的生物糖胶-1、1.2％的透明质酸钠、0.9％的矮地茶杆提取物、0.7％的海茴香愈伤组织培养物滤液、0.6％的酵母菌/大米发酵产物滤液、0.8％的裂殖酵母菌丝体发酵产物滤液、0.9％的乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、0.7％的乳酸杆菌发酵产物、0.6％的芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、0.7％的二裂酵母发酵产物溶胞物、0.8％的嗜热链球菌发酵产物、0.1％的胶态银和73.2％的去离子水；所述的精华素置于一密封容器中，精华素中注入有氢气。
上述精华素通过以下步骤制得：
(1)将丁二醇、吡咯烷酮羧酸钠、聚谷酸氨钠、生物糖胶-1、透明质酸钠和去离子水混合加热至75℃搅拌至完全溶解，得到混合物；
(2)将步骤(1)中得到混合物倒入真空均质乳化机内，抽真空均质搅拌叶片，搅拌速度为600rpm，均质速度为1800rpm，抽真空至0.04Mpa,均质搅拌10分钟；
(3)泄去真空压力，将辛酸/癸酸/琥珀酸甘油三酯加入真空均质乳化机内，开启搅拌速度600rpm，均质速度1800rpm，均质搅拌3分钟；
(4)泄去真空压力，将矮地茶杆提取物、海茴香愈伤组织培养物滤液、酵母菌/大米发酵产物滤液、裂殖酵母菌丝体发酵产物滤液、乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、乳酸杆菌发酵产物、芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、二裂酵母发酵产物溶胞物、嗜热链球菌发酵产物、胶态银依次加入真空均质乳化机内，均质搅拌5分钟；
(5)继续搅拌待温度降至35℃后出料，用100目不锈钢滤网过滤装桶备用，得到精华素半成品；
(6)将半成品注入到密封容器中，在半成品内注入氢气，得到成品。
步骤(4)中的矮地茶杆提取物由矮地茶杆通过粉碎机粉碎，利用超临界萃取方式，以二氧化碳配合适量的变性乙醇当成溶剂，调整适当的温度与压力，泄压后制得。
步骤(6)中，密封容器中注入氢气的浓度控制在3ppm。
实施例2
本实施例涉及一种复合多种后生元赋活精华素,按重量百分比计，其包括：8.0％的丁二醇、2.0％的辛酸/癸酸/琥珀酸甘油三酯、2.0％的吡咯烷酮羧酸钠、2.0％的聚谷酸氨钠、1.0％的生物糖胶-1、1.0％的透明质酸钠、0.5％的矮地茶杆提取物、0.50％的海茴香愈伤组织培养物滤液、0.5％的酵母菌/大米发酵产物滤液、0.5％的裂殖酵母菌丝体发酵产物滤液、0.5％的乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、0.5％的乳酸杆菌发酵产物、0.5％的芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、0.5％的二裂酵母发酵产物溶胞物、0.5％的嗜热链球菌发酵产物、0.1％的胶态银和79.4％的去离子水；所述的精华素置于一密封容器中，精华素中注入有氢气。
上述精华素通过以下步骤制得：
(1)将丁二醇、吡咯烷酮羧酸钠、聚谷酸氨钠、生物糖胶-1、透明质酸钠和去离子水混合加热至75℃搅拌至完全溶解，得到混合物；
(2)将步骤(1)中得到混合物倒入真空均质乳化机内，抽真空均质搅拌叶片，搅拌速度为600rpm，均质速度为1800rpm，抽真空至0.04Mpa,均质搅拌10分钟；
(3)泄去真空压力，将辛酸/癸酸/琥珀酸甘油三酯加入真空均质乳化机内，开启搅拌速度600rpm，均质速度1800rpm，均质搅拌3分钟；
(4)泄去真空压力，将矮地茶杆提取物、海茴香愈伤组织培养物滤液、酵母菌/大米发酵产物滤液、裂殖酵母菌丝体发酵产物滤液、乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、乳酸杆菌发酵产物、芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、二裂酵母发酵产物溶胞物、嗜热链球菌发酵产物、胶态银依次加入真空均质乳化机内，均质搅拌5分钟；
(5)继续搅拌待温度降至35℃后出料，用100目不锈钢滤网过滤装桶备用，得到精华素半成品；
(6)将半成品注入到密封容器中，在半成品内注入氢气，得到成品。
步骤(4)中的矮地茶杆提取物由矮地茶杆通过粉碎机粉碎，利用超临界萃取方式，以二氧化碳配合适量的变性乙醇当成溶剂，调整适当的温度与压力，泄压后制得。
步骤步骤(6)中，密封容器中注入氢气的浓度控制在1ppm。
实施例3
本实施例涉及一种复合多种后生元赋活精华素,按重量百分比计，其包括：8.0％的丁二醇、2.0％的辛酸/癸酸/琥珀酸甘油三酯、2.0％的吡咯烷酮羧酸钠、2.0％的聚谷酸氨钠、1.0％的生物糖胶-1、1.0％的透明质酸钠、0.5％的矮地茶杆提取物、0.5％的海茴香愈伤组织培养物滤液、0.5％的酵母菌/大米发酵产物滤液、0.5％的裂殖酵母菌丝体发酵产物滤液、0.5％的乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、0.5％的乳酸杆菌发酵产物、0.5％的芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、0.5％的二裂酵母发酵产物溶胞物、0.5％的嗜热链球菌发酵产物、0.1％的胶态银和79.4％的去离子水；所述的精华素置于一密封容器中，精华素中注入有氢气。
上述精华素通过以下步骤制得：
(1)将丁二醇、吡咯烷酮羧酸钠、聚谷酸氨钠、生物糖胶-1、透明质酸钠和去离子水混合加热至75℃搅拌至完全溶解，得到混合物；
(2)将步骤(1)中得到混合物倒入真空均质乳化机内，抽真空均质搅拌叶片，搅拌速度为600rpm，均质速度为1800rpm，抽真空至0.04Mpa,均质搅拌10分钟；
(3)泄去真空压力，将辛酸/癸酸/琥珀酸甘油三酯加入真空均质乳化机内，开启搅拌速度600rpm，均质速度1800rpm，均质搅拌3分钟；
(4)泄去真空压力，将矮地茶杆提取物、海茴香愈伤组织培养物滤液、酵母菌/大米发酵产物滤液、裂殖酵母菌丝体发酵产物滤液、乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、乳酸杆菌发酵产物、芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、二裂酵母发酵产物溶胞物、嗜热链球菌发酵产物、胶态银依次加入真空均质乳化机内，均质搅拌5分钟；
(5)继续搅拌待温度降至35℃后出料，用100目不锈钢滤网过滤装桶备用，得到精华素半成品；
(6)将半成品注入到密封容器中，在半成品内注入氢气，得到成品。
步骤(4)中的矮地茶杆提取物由矮地茶杆通过粉碎机粉碎，利用超临界萃取方式，以二氧化碳配合适量的变性乙醇当成溶剂，调整适当的温度与压力，泄压后制得。
步骤(6)中，密封容器中注入氢气的浓度控制在3ppm。
实施例4
本实施例涉及一种复合多种后生元赋活精华素,按重量百分比计，其包括：9.0％的丁二醇、2.0％的辛酸/癸酸/琥珀酸甘油三酯、3.0％的吡咯烷酮羧酸钠、2.0％的聚谷酸氨钠、2.0％的生物糖胶-1、1.0％的透明质酸钠、1.0％的矮地茶杆提取物、0.5％的海茴香愈伤组织培养物滤液、0.5％的酵母菌/大米发酵产物滤液、1.0％的裂殖酵母菌丝体发酵产物滤液、0.5％的乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、0.5％的乳酸杆菌发酵产物、1.0％的芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、0.5％的二裂酵母发酵产物溶胞物、1.0％的嗜热链球菌发酵产物、0.1％的胶态银和74.4％的去离子水；所述的精华素置于一密封容器中，精华素中注入有氢气。
上述精华素通过以下步骤制得：
(1)将丁二醇、吡咯烷酮羧酸钠、聚谷酸氨钠、生物糖胶-1、透明质酸钠和去离子水混合加热至75℃搅拌至完全溶解，得到混合物；
(2)将步骤(1)中得到混合物倒入真空均质乳化机内，抽真空均质搅拌叶片，搅拌速度为600rpm，均质速度为1800rpm，抽真空至0.04Mpa,均质搅拌10分钟；
(3)泄去真空压力，将辛酸/癸酸/琥珀酸甘油三酯加入真空均质乳化机内，开启搅拌速度600rpm，均质速度1800rpm，均质搅拌3分钟；
(4)泄去真空压力，将矮地茶杆提取物、海茴香愈伤组织培养物滤液、酵母菌/大米发酵产物滤液、裂殖酵母菌丝体发酵产物滤液、乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、乳酸杆菌发酵产物、芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、二裂酵母发酵产物溶胞物、嗜热链球菌发酵产物、胶态银依次加入真空均质乳化机内，均质搅拌5分钟；
(5)继续搅拌待温度降至35℃后出料，用100目不锈钢滤网过滤装桶备用，得到精华素半成品；
(6)将半成品注入到密封容器中，在半成品内注入氢气，得到成品。
步骤(4)中的矮地茶杆提取物由矮地茶杆通过粉碎机粉碎，利用超临界萃取方式，以二氧化碳配合适量的变性乙醇当成溶剂，调整适当的温度与压力，泄压后制得。
步骤(6)中，密封容器中注入氢气的浓度控制在3ppm。
实施例5
本实施例涉及一种复合多种后生元赋活精华素,按重量百分比计，其包括：13.0％的丁二醇、2.5％的辛酸/癸酸/琥珀酸甘油三酯、2.5％的吡咯烷酮羧酸钠、3.0％的聚谷酸氨钠、1.0％的生物糖胶-1、1.2％的透明质酸钠、0.6％的矮地茶杆提取物、0.5％的海茴香愈伤组织培养物滤液、1.0％的酵母菌/大米发酵产物滤液、0.6％的裂殖酵母菌丝体发酵产物滤液、0.7％的乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、0.5％的乳酸杆菌发酵产物、0.8％的芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、0.7％的二裂酵母发酵产物溶胞物、1.0％的嗜热链球菌发酵产物、0.2％的胶态银和71.2％的去离子水；所述的精华素置于一密封容器中，精华素中注入有氢气。
上述精华素通过以下步骤制得：
(1)将丁二醇、吡咯烷酮羧酸钠、聚谷酸氨钠、生物糖胶-1、透明质酸钠和去离子水混合加热至75℃搅拌至完全溶解，得到混合物；
(2)将步骤(1)中得到混合物倒入真空均质乳化机内，抽真空均质搅拌叶片，搅拌速度为600rpm，均质速度为1800rpm，抽真空至0.04Mpa,均质搅拌10分钟；
(3)泄去真空压力，将辛酸/癸酸/琥珀酸甘油三酯加入真空均质乳化机内，开启搅拌速度600rpm，均质速度1800rpm，均质搅拌3分钟；
(4)泄去真空压力，将矮地茶杆提取物、海茴香愈伤组织培养物滤液、酵母菌/大米发酵产物滤液、裂殖酵母菌丝体发酵产物滤液、乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、乳酸杆菌发酵产物、芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、二裂酵母发酵产物溶胞物、嗜热链球菌发酵产物、胶态银依次加入真空均质乳化机内，均质搅拌5分钟；
(5)继续搅拌待温度降至35℃后出料，用100目不锈钢滤网过滤装桶备用，得到精华素半成品；
(6)将半成品注入到密封容器中，在半成品内注入氢气，得到成品。
步骤(4)中的矮地茶杆提取物由矮地茶杆通过粉碎机粉碎，利用超临界萃取方式，以二氧化碳配合适量的变性乙醇当成溶剂，调整适当的温度与压力，泄压后制得。
步骤(6)中，密封容器中注入氢气的浓度控制在3ppm。
实施例6
本实施例涉及一种复合多种后生元赋活精华素,按重量百分比计，其包括：12.0％的丁二醇、2.5％的辛酸/癸酸/琥珀酸甘油三酯、3％的吡咯烷酮羧酸钠、2.5％的聚谷酸氨钠、1.2％的生物糖胶-1、1.5％的透明质酸钠、1.0％的矮地茶杆提取物、1.0％的海茴香愈伤组织培养物滤液、0.6％的酵母菌/大米发酵产物滤液、0.5％的裂殖酵母菌丝体发酵产物滤液、0.9％的乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、0.9％的乳酸杆菌发酵产物、0.5％的芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、0.6％的二裂酵母发酵产物溶胞物、1.0％的嗜热链球菌发酵产物、0.2％的胶态银和70.1％的去离子水；所述的精华素置于一密封容器中，精华素中注入有氢气。
上述精华素通过以下步骤制得：
(1)将丁二醇、吡咯烷酮羧酸钠、聚谷酸氨钠、生物糖胶-1、透明质酸钠和去离子水混合加热至75℃搅拌至完全溶解，得到混合物；
(2)将步骤(1)中得到混合物倒入真空均质乳化机内，抽真空均质搅拌叶片，搅拌速度为600rpm，均质速度为1800rpm，抽真空至0.04Mpa,均质搅拌10分钟；
(3)泄去真空压力，将辛酸/癸酸/琥珀酸甘油三酯加入真空均质乳化机内，开启搅拌速度600rpm，均质速度1800rpm，均质搅拌3分钟；
(4)泄去真空压力，将矮地茶杆提取物、海茴香愈伤组织培养物滤液、酵母菌/大米发酵产物滤液、裂殖酵母菌丝体发酵产物滤液、乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、乳酸杆菌发酵产物、芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、二裂酵母发酵产物溶胞物、嗜热链球菌发酵产物、胶态银依次加入真空均质乳化机内，均质搅拌5分钟；
(5)继续搅拌待温度降至35℃后出料，用100目不锈钢滤网过滤装桶备用，得到精华素半成品；
(6)将半成品注入到密封容器中，在半成品内注入氢气，得到成品。
步骤(4)中的矮地茶杆提取物由矮地茶杆通过粉碎机粉碎，利用超临界萃取方式，以二氧化碳配合适量的变性乙醇当成溶剂，调整适当的温度与压力，泄压后制得。
步骤(6)中，密封容器中注入氢气后的压强为2Mpa。
对比例1
本对比例涉及一种复合多种后生元赋活精华素，按重量百分比计，其包括：10％的丁二醇、2.4％的辛酸/癸酸/琥珀酸甘油三酯、2.6％的吡咯烷酮羧酸钠、2.5％的聚谷酸氨钠、1.3％的生物糖胶-1、1.2％的透明质酸钠、0.9％的矮地茶杆提取物、0.7％的海茴香愈伤组织培养物滤液、0.6％的酵母菌/大米发酵产物滤液、0.8％的裂殖酵母菌丝体发酵产物滤液、0.9％的乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、0.7％的乳酸杆菌发酵产物、0.6％的芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、0.7％的二裂酵母发酵产物溶胞物、0.8％的嗜热链球菌发酵产物、0.1％的胶态银和73.2％的去离子水。
上述精华素通过以下步骤制得：
(1)将丁二醇、吡咯烷酮羧酸钠、聚谷酸氨钠、生物糖胶-1、透明质酸钠和去离子水混合加热至75℃搅拌至完全溶解，得到混合物；
(2)将步骤(1)中得到混合物倒入真空均质乳化机内，抽真空均质搅拌叶片，搅拌速度为600rpm，均质速度为1800rpm，抽真空至0.04Mpa,均质搅拌10分钟；
(3)泄去真空压力，将辛酸/癸酸/琥珀酸甘油三酯加入真空均质乳化机内，开启搅拌速度600rpm，均质速度1800rpm，均质搅拌3分钟；
(4)泄去真空压力，将矮地茶杆提取物、海茴香愈伤组织培养物滤液、酵母菌/大米发酵产物滤液、裂殖酵母菌丝体发酵产物滤液、乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、乳酸杆菌发酵产物、芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、二裂酵母发酵产物溶胞物、嗜热链球菌发酵产物、胶态银依次加入真空均质乳化机内，均质搅拌5分钟；
(5)继续搅拌待温度降至35℃后出料，用100目不锈钢滤网过滤装桶备用，得到成品。
步骤(4)中的矮地茶杆提取物由矮地茶杆通过粉碎机粉碎，利用超临界萃取方式，以二氧化碳配合适量的变性乙醇当成溶剂，调整适当的温度与压力，泄压后制得。
对比例2
本对比例涉及一种复合多种后生元赋活精华素，按重量百分比计，其包括：10％的丁二醇、2.4％的辛酸/癸酸/琥珀酸甘油三酯、2.6％的吡咯烷酮羧酸钠、2.5％的聚谷酸氨钠、1.3％的生物糖胶-1、1.2％的透明质酸钠、0.7％的海茴香愈伤组织培养物滤液、0.6％的酵母菌/大米发酵产物滤液、0.8％的裂殖酵母菌丝体发酵产物滤液、0.9％的乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、0.7％的乳酸杆菌发酵产物、0.6％的芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、0.7％的二裂酵母发酵产物溶胞物、0.8％的嗜热链球菌发酵产物、0.1％的胶态银和73.2％的去离子水；所述的精华素置于一密封容器中，精华素中注入有氢气。
上述精华素通过以下步骤制得：
(1)将丁二醇、吡咯烷酮羧酸钠、聚谷酸氨钠、生物糖胶-1、透明质酸钠和去离子水混合加热至75℃搅拌至完全溶解，得到混合物；
(2)将步骤(1)中得到混合物倒入真空均质乳化机内，抽真空均质搅拌叶片，搅拌速度为600rpm，均质速度为1800rpm，抽真空至0.04Mpa,均质搅拌10分钟；
(3)泄去真空压力，将辛酸/癸酸/琥珀酸甘油三酯加入真空均质乳化机内，开启搅拌速度600rpm，均质速度1800rpm，均质搅拌3分钟；
(4)抽真空搅拌降温至45℃时，将海茴香愈伤组织培养物滤液、酵母菌/大米发酵产物滤液、裂殖酵母菌丝体发酵产物滤液、乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、乳酸杆菌发酵产物、芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、二裂酵母发酵产物溶胞物、嗜热链球菌发酵产物、胶态银依次加入真空均质乳化机内，均质搅拌5分钟；
(5)继续搅拌待温度降至35℃后出料，用100目不锈钢滤网过滤装桶备用，得到精华素半成品；
(6)将半成品注入到密封容器中，在半成品内注入氢气，得到成品。密封容器中注入氢气的浓度控制在3ppm。
对比例3
本对比例涉及一种复合多种后生元赋活精华素，按重量百分比计，其包括：10％的丁二醇、2.4％的辛酸/癸酸/琥珀酸甘油三酯、2.6％的吡咯烷酮羧酸钠、2.5％的聚谷酸氨钠、1.3％的生物糖胶-1、1.2％的透明质酸钠、0.7％的海茴香愈伤组织培养物滤液、0.6％的酵母菌/大米发酵产物滤液、0.8％的裂殖酵母菌丝体发酵产物滤液、0.9％的乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、0.7％的乳酸杆菌发酵产物、0.6％的芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、0.7％的二裂酵母发酵产物溶胞物、0.8％的嗜热链球菌发酵产物、0.1％的胶态银和73.2％的去离子水。
上述精华素通过以下步骤制得：
(1)将丁二醇、吡咯烷酮羧酸钠、聚谷酸氨钠、生物糖胶-1、透明质酸钠和去离子水混合加热至75℃搅拌至完全溶解，得到混合物；
(2)将步骤(1)中得到混合物倒入真空均质乳化机内，抽真空均质搅拌叶片，搅拌速度为600rpm，均质速度为1800rpm，抽真空至0.04Mpa,均质搅拌10分钟；
(3)泄去真空压力，将辛酸/癸酸/琥珀酸甘油三酯加入真空均质乳化机内，开启搅拌速度600rpm，均质速度1800rpm，均质搅拌3分钟；
(4)抽真空搅拌降温至45℃时，将海茴香愈伤组织培养物滤液、酵母菌/大米发酵产物滤液、裂殖酵母菌丝体发酵产物滤液、乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、乳酸杆菌发酵产物、芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、二裂酵母发酵产物溶胞物、嗜热链球菌发酵产物、胶态银依次加入真空均质乳化机内，均质搅拌5分钟；
(5)继续搅拌待温度降至35℃后出料，用100目不锈钢滤网过滤装桶备用，得到成品。
效果实施例
将精华素装在密闭容器中，在使用时，挤出精华素后，需要马上密封容器。为了解本发明的实际使用效果，按实施例1-6和对比例1-3中的组分配比制得精华素，以问卷调查的形式对本产品开展了广泛的试用调查，本调查共纳入全国各地男女经常性过敏发红起疹症状试用者2700人，每个组份的试用者各300人，其中男性1478人，女性1222人，年龄最大55岁，最小16岁，平均年龄40岁左右，共收回有效问卷2156份。
上述对比例1至对比例3和实施例1至实施例6中的精华素的护肤效果如表1所示。
表1
综上所述，该产品对提升皮肤暗沉度、改善皮肤保湿感、降低过敏红斑量、除皮肤起疹量、降低过敏褪红起疹再发性有不同程度的显著改善，可以达到良好的治愈消费者经常性过敏褪红起疹功效。
矮地茶干提取物对消除皮肤起疹量具有显著效果，可以达到修复皮肤的效果，精华素中注入氢气后，活性物组合对降低过敏红斑量和降低过敏褪红起疹再发性具有突出的作用。
实施例1中各组份的配比达到的护肤效果最好。
以上所述仅为本发明的实施例，并非因此限制本发明的专利范围，凡是利用本发明说明书内容所作的等效结构或等效流程变换，或直接或间接运用在其它相关的技术领域，均同理包括在本发明的专利保护范围内。
Claims (9)
1.一种复合多种后生元赋活精华素，其特征在于：按重量百分比计，其包括：8.0～13.0％的丁二醇、2.0～3.0％的辛酸/癸酸/琥珀酸甘油三酯、2.0～3.0％的吡咯烷酮羧酸钠、2.0～3.0％的聚谷酸氨钠、1.0～2.0％的生物糖胶-1、1.0～1.5％的透明质酸钠、0.5～1.0％的矮地茶杆提取物、0.5～1.0％的海茴香愈伤组织培养物滤液、0.5～1.0％的酵母菌/大米发酵产物滤液、0.5～1.0％的裂殖酵母菌丝体发酵产物滤液、0.5～1.0％的乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、0.5～1.0％的乳酸杆菌发酵产物、0.5～1.0％的芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、0.5～1.0％的二裂酵母发酵产物溶胞物、0.5～1.0％的嗜热链球菌发酵产物、0.1～0.2％的胶态银和65.3～79.4％的去离子水；所述的精华素置于一密封容器中，精华素中注入有氢气。
2.根据权利要求1所述的复合多种后生元赋活精华素，其特征在于：按重量百分比计，其包括：10％的丁二醇、2.4％的辛酸/癸酸/琥珀酸甘油三酯、2.6％的吡咯烷酮羧酸钠、2.5％的聚谷酸氨钠、1.3％的生物糖胶-1、1.2％的透明质酸钠、0.9％的矮地茶杆提取物、0.7％的海茴香愈伤组织培养物滤液、0.6％的酵母菌/大米发酵产物滤液、0.8％的裂殖酵母菌丝体发酵产物滤液、0.9％的乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、0.7％的乳酸杆菌发酵产物、0.6％的芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、0.7％的二裂酵母发酵产物溶胞物、0.8％的嗜热链球菌发酵产物、0.1％的胶态银和73.2％的去离子水；所述的精华素置于一密封容器中，精华素中注入有氢气。
3.根据权利要求1所述的复合多种后生元赋活精华素，其特征在于：所述的矮地茶杆提取物由矮地茶杆通过粉碎机粉碎，利用超临界萃取方式，以二氧化碳配合适量的变性乙醇当成溶剂，调整适当的温度与压力，泄压后制得。
4.一种如权利要求1所述的复合多种后生元赋活精华素的制备方法，其特征在于：其包括以下步骤：
(1)将丁二醇、吡咯烷酮羧酸钠、聚谷酸氨钠、生物糖胶-1、透明质酸钠和去离子水混合加热至75～80℃搅拌至完全溶解，得到混合物；
(2)将步骤(1)中得到混合物倒入真空均质乳化机内，开始搅拌，搅拌速度为500～700rpm，均质速度为1600～2000rpm，抽真空至0.03～0.05Mpa,均质搅拌3-10分钟；
(3)泄去真空压力，将辛酸/癸酸/琥珀酸甘油三酯加入真空均质乳化机内，开启搅拌速度500～700rpm，均质速度1600～2000rpm，抽真空均质搅拌2-5分钟；
(4)泄去真空压力，将矮地茶杆提取物、海茴香愈伤组织培养物滤液、酵母菌/大米发酵产物滤液、裂殖酵母菌丝体发酵产物滤液、乳酸杆菌/绿豆籽提取物/谷氨酸钠发酵产物滤液、乳酸杆菌发酵产物、芽孢杆菌/米糠提取物/大豆提取物发酵产物滤液、二裂酵母发酵产物溶胞物、嗜热链球菌发酵产物、胶态银依次加入真空均质乳化机内，均质搅拌5分钟；
(5)继续搅拌待温度降至35℃后出料，用80～120目不锈钢滤网过滤装桶备用，得到精华素半成品；
(6)将半成品注入到密封容器中，在半成品内注入氢气，氢气浓度控制在0.5ppm～5ppm，得到包装成品。
5.根据权利要求4所述的复合多种后生元赋活精华素的制备方法，其特征在于，步骤(4)中的矮地茶杆提取物由矮地茶杆通过粉碎机粉碎，利用超临界萃取方式，以二氧化碳配合适量的变性乙醇当成溶剂，调整适当的温度与压力，泄压后制得。
6.根据权利要求4所述的复合多种后生元赋活精华素的制备方法，其特征在于，步骤(2)中，搅拌速度为600rpm，均质速度为1800rpm。
7.根据权利要求4所述的复合多种后生元赋活精华素的制备方法，其特征在于，步骤(2)中，真空均质乳化机抽真空至0.04Mpa。
8.根据权利要求4所述的复合多种后生元赋活精华素的制备方法，其特征在于，步骤(3)中，搅拌速度为600rpm，均质速度1800rpm。
9.根据权利要求4所述的复合多种后生元赋活精华素的制备方法，其特征在于，步骤(6)中，密封容器中注入氢气的浓度控制在3ppm。
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911120976.1A CN110772433A (zh) | 2019-11-15 | 2019-11-15 | 一种复合多种后生元赋活精华素及制备方法 |
| US17/624,319 US20220354913A1 (en) | 2019-11-15 | 2020-11-03 | An active essence compounded with postbiotics and preparation method |
| PCT/CN2020/126073 WO2021093632A1 (zh) | 2019-11-15 | 2020-11-03 | 一种复合多种后生元赋活精华素及制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911120976.1A CN110772433A (zh) | 2019-11-15 | 2019-11-15 | 一种复合多种后生元赋活精华素及制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110772433A true CN110772433A (zh) | 2020-02-11 |
Family
ID=69391496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911120976.1A Pending CN110772433A (zh) | 2019-11-15 | 2019-11-15 | 一种复合多种后生元赋活精华素及制备方法 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20220354913A1 (zh) |
| CN (1) | CN110772433A (zh) |
| WO (1) | WO2021093632A1 (zh) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111700856A (zh) * | 2020-07-21 | 2020-09-25 | 广州蜜妆生物科技有限公司 | 一种含微油珠的护肤精华 |
| IT202000017188A1 (it) * | 2020-07-15 | 2020-10-15 | O F I Officina Farm Italiana S P A | Composizione dermatologica per il riequilibrio della pelle, per aumentarne l’idratazione e l’elasticità e per ridurne le discromie |
| CN112494399A (zh) * | 2020-12-14 | 2021-03-16 | 广州欧正化妆品技术研究院有限公司 | 一种含酵母菌大米发酵产物滤液的保湿亮肤修复精华及其制备方法 |
| CN112516027A (zh) * | 2020-12-15 | 2021-03-19 | 广州市拉凯尔干细胞研究所 | 一种发酵护肤组合物 |
| JP6933867B1 (ja) * | 2021-02-15 | 2021-09-08 | 株式会社ファーマフーズ | 頭部のフケ、かゆみ又は脱毛の予防又は軽減剤 |
| CN116473857A (zh) * | 2023-04-03 | 2023-07-25 | 广东丸美生物技术股份有限公司 | 油芯凝珠、制备方法以及化妆品 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11517597B2 (en) * | 2020-09-29 | 2022-12-06 | Chambio Co., Ltd. | Method for improving skin condition with postbiotic extract |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106361684A (zh) * | 2016-08-31 | 2017-02-01 | 广东芭薇生物科技股份有限公司 | 一种调节皮肤表面微生物生态平衡的活性组合物 |
| CN106727121A (zh) * | 2016-12-19 | 2017-05-31 | 哈尔滨灵草舒生物科技有限公司 | 节节草防晒沐浴调理乳的制备方法 |
| CN107184411A (zh) * | 2017-04-21 | 2017-09-22 | 韩后化妆品股份有限公司 | 一种复合水嫩因子、化妆品及化妆品的制备方法 |
| CN107281082A (zh) * | 2017-06-29 | 2017-10-24 | 广州大澳化妆品有限公司 | 一种含小分子肽的营养液及包括它的面膜和制作方法 |
| CN108403457A (zh) * | 2018-04-18 | 2018-08-17 | 淮北市儒伽医疗科技有限公司 | 一种用于红血丝修复面膜液及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003073219A (ja) * | 2001-08-30 | 2003-03-12 | Nikko Seiyaku Kk | ビタミンｃ誘導体と油溶性甘草エキスを配合した外用剤 |
| CN101962385A (zh) * | 2010-10-19 | 2011-02-02 | 南京泽朗医药科技有限公司 | 一种岩白菜素的制备方法 |
| CN104490748A (zh) * | 2015-01-08 | 2015-04-08 | 上海圣婕化妆品有限公司 | 一种益生菌复合物及其应用 |
| CN104586737A (zh) * | 2015-01-08 | 2015-05-06 | 上海圣婕化妆品有限公司 | 一种益生菌美白修复面膜精华液及其制备方法 |
| CN107184623A (zh) * | 2017-07-06 | 2017-09-22 | 天津中医药大学 | 一种矮地茶醇提物的制备方法及其应用 |
| CN108338965B (zh) * | 2018-04-07 | 2020-09-11 | 广州市索柔生物科技有限公司 | 一种五谷杂粮组合物及其制备方法 |
-
2019
- 2019-11-15 CN CN201911120976.1A patent/CN110772433A/zh active Pending
-
2020
- 2020-11-03 WO PCT/CN2020/126073 patent/WO2021093632A1/zh active Application Filing
- 2020-11-03 US US17/624,319 patent/US20220354913A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106361684A (zh) * | 2016-08-31 | 2017-02-01 | 广东芭薇生物科技股份有限公司 | 一种调节皮肤表面微生物生态平衡的活性组合物 |
| CN106727121A (zh) * | 2016-12-19 | 2017-05-31 | 哈尔滨灵草舒生物科技有限公司 | 节节草防晒沐浴调理乳的制备方法 |
| CN107184411A (zh) * | 2017-04-21 | 2017-09-22 | 韩后化妆品股份有限公司 | 一种复合水嫩因子、化妆品及化妆品的制备方法 |
| CN107281082A (zh) * | 2017-06-29 | 2017-10-24 | 广州大澳化妆品有限公司 | 一种含小分子肽的营养液及包括它的面膜和制作方法 |
| CN108403457A (zh) * | 2018-04-18 | 2018-08-17 | 淮北市儒伽医疗科技有限公司 | 一种用于红血丝修复面膜液及其制备方法 |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202000017188A1 (it) * | 2020-07-15 | 2020-10-15 | O F I Officina Farm Italiana S P A | Composizione dermatologica per il riequilibrio della pelle, per aumentarne l’idratazione e l’elasticità e per ridurne le discromie |
| WO2022013897A1 (en) * | 2020-07-15 | 2022-01-20 | O.F.I. Officina Farmaceutica Italiana S.P.A. | Dermatological composition for rebalancing the skin, for increasing its hydration and elasticity and for reducing dynamic disorders |
| CN111700856A (zh) * | 2020-07-21 | 2020-09-25 | 广州蜜妆生物科技有限公司 | 一种含微油珠的护肤精华 |
| CN112494399A (zh) * | 2020-12-14 | 2021-03-16 | 广州欧正化妆品技术研究院有限公司 | 一种含酵母菌大米发酵产物滤液的保湿亮肤修复精华及其制备方法 |
| CN112516027A (zh) * | 2020-12-15 | 2021-03-19 | 广州市拉凯尔干细胞研究所 | 一种发酵护肤组合物 |
| JP6933867B1 (ja) * | 2021-02-15 | 2021-09-08 | 株式会社ファーマフーズ | 頭部のフケ、かゆみ又は脱毛の予防又は軽減剤 |
| WO2022172511A1 (ja) * | 2021-02-15 | 2022-08-18 | 株式会社ファーマフーズ | 頭部のフケ、かゆみ又は脱毛の予防又は軽減剤 |
| JP2022124152A (ja) * | 2021-02-15 | 2022-08-25 | 株式会社ファーマフーズ | 頭部のフケ、かゆみ又は脱毛の予防又は軽減剤 |
| CN116473857A (zh) * | 2023-04-03 | 2023-07-25 | 广东丸美生物技术股份有限公司 | 油芯凝珠、制备方法以及化妆品 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021093632A1 (zh) | 2021-05-20 |
| US20220354913A1 (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110772433A (zh) | 一种复合多种后生元赋活精华素及制备方法 | |
| CN107616956A (zh) | 一种芦荟护肤组合物及其制备方法 | |
| WO2020207313A1 (zh) | 手掌参提取方法及相关手掌参提取物 | |
| CN112999127B (zh) | 一种龙胆复方酵素及其制备方法和应用 | |
| CN105878102A (zh) | 一种含有石榴果提取物的面膜及其制备方法 | |
| CN113134087B (zh) | 一种含有生物多糖的组合物及其应用 | |
| CN115501143B (zh) | 一种含有雪莲培养物的抗敏舒缓组合物及其制备方法 | |
| CN116807952A (zh) | 一种植物提取活性组合物及其制备方法 | |
| KR102499346B1 (ko) | 천연복합발효액과 이를 이용하여 활성성분을 증대시키고 체내흡수율을 개선시킨 고상발효 초미세분말 | |
| CN113018246B (zh) | 一种具有缓解头皮炎症的益生菌洗发水及其制备方法 | |
| CN111700831B (zh) | 一种具有祛皱功效的抗衰老护肤品组合物、制备方法及其应用 | |
| CN105267102A (zh) | 一种天然植物抗衰老面霜及其制备方法 | |
| KR102016640B1 (ko) | 포제 추출물을 포함하는 조성물 | |
| CN111821230A (zh) | 一种防敏修复的化妆品组合物及其应用 | |
| CN110037968B (zh) | 一种含有石斛提取液的防皱贴片及其制备方法 | |
| KR20150081892A (ko) | 돼지감자 추출물을 함유하는 화장료 조성물 | |
| CN114317651B (zh) | 一种黄精多肽、制备方法及其应用 | |
| CN105176724A (zh) | 一种促进免疫、益肾、明目和养颜葡萄酒的生产方法 | |
| CN114432384A (zh) | 一种低氘水龙脑雾化护眼液 | |
| CN110664700B (zh) | 组合物及其在制备防治痤疮的产品中的应用 | |
| CN106606448A (zh) | 一种抗氧化酵素面膜液 | |
| KR101956749B1 (ko) | 혼합생약 화장료 조성물의 제조방법 및 이를 통해 제조된 혼합생약 화장료 조성물 | |
| CN110934785A (zh) | 一种美白保湿敏感肌肤用洗面奶及其制备方法 | |
| KR20210026948A (ko) | 백년초 추출물을 유효성분으로 하는 피부 트러블 개선용 크림 화장료 조성물 | |
| CN118021691B (zh) | 一种深度补水的化妆品组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |